Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells

Breast Cancer Research

Volumn 16, Issue 4, 2014, Pages

  Zhao, Zuowei ^a   Lu, Ping ^a   Zhang, Hao ^a   Xu, Huanming ^b   Gao, Ningning ^b   Li, Man ^a   Liu, Caigang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AXIN; BETA CATENIN; CYCLIN D; GELATINASE A; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; MATRILYSIN; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; NESTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UVOMORULIN; VASCULOTROPIN; VIMENTIN; WNT PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; COLON POLYPOSIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENETIC MANIPULATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; WNT SIGNALING PATHWAY; ANIMAL; BREAST TUMOR; CANCER STEM CELL; CELL CYCLE; CELL MOTION; CELL TRANSFORMATION; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HETEROGRAFTS; HUMANS; NEOPLASTIC STEM CELLS; NESTIN; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84905842615     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0408-8     Document Type: Article

References (43)

1. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010, 11:339-349. 10.1016/S1470-2045(10)70008-5, 20181526.
2. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 2012, 23:2223-2234. 10.1093/annonc/mds067, 22517820.
3. Reeder-Hayes KE, Carey LA, Sikov WM. Clinical trials in triple negative breast cancer. Breast Dis 2010, 32:123-136. 21778571.
4. Jaspers JE, Rottenberg S, Jonkers J. Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochim Biophys Acta 2009, 1796:266-280. 19616605.
5. Tropepe V, Alton K, Sachewsky N, Cheng V, Kuo C, Morshead CM. Neurogenic potential of isolated precursor cells from early post-gastrula somitic tissue. Stem Cells Dev 2009, 18:1533-1542. 10.1089/scd.2008.0359, 19326969.
6. Sahlgren CM, Pallari HM, He T, Chou YH, Goldman RD, Eriksson JE. A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. EMBO J 2006, 25:4808-4819. 10.1038/sj.emboj.7601366, 17036052.
7. Parry S, Savage K, Marchio C, Reis-Filho JS. Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol 2008, 61:1045-1050. 10.1136/jcp.2008.058750, 18641405.
8. Strojnik T, Rosland GV, Sakariassen PO, Kavalar R, Lah T. Neural stem cell markers nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 2007, 68:133-143. 10.1016/j.surneu.2006.10.050, 17537489.
9. Zimmerman L, Parr B, Lendahl U, Cunningham M, McKay R, Gavin B, Mann J, Vassileva G, McMahon A. Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors. Neuron 1994, 12:11-24. 10.1016/0896-6273(94)90148-1, 8292356.
10. Piras F, Perra MT, Murtas D, Minerba L, Floris C, Maxia C, Demurtas P, Ugalde J, Ribatti D, Sirigu P. The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep 2010, 23:17-24. 19956860.
11. Ehrmann J, Kolar Z, Mokry J. Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol 2005, 58:222-223. 10.1136/jcp.2004.021238, 15677549.
12. Teranishi N, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Seya T, Shinji S, Tajiri T. Identification of neovasculature using nestin in colorectal cancer. Int J Oncol 2007, 30:593-603. 17273760.
13. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, Berman DM. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 2007, 67:9199-9206. 10.1158/0008-5472.CAN-07-0806, 17909025.
14. Rogelsperger O, Ekmekcioglu C, Jager W, Klimpfinger M, Konigsberg R, Krenbek D, Sellner F, Thalhammer T. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res 2009, 46:422-432. 10.1111/j.1600-079X.2009.00679.x, 19552766.
15. Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, Godwin AK, Wells W, DiRenzo J. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 2007, 67:501-510. 10.1158/0008-5472.CAN-05-4571, 17234757.
16. Liu C, Chen B, Zhu J, Zhang R, Yao F, Jin F, Xu H, Lu P. Clinical implications for nestin protein expression in breast cancer. Cancer Sci 2010, 101:815-819. 10.1111/j.1349-7006.2009.01422.x, 20028381.
17. Piras F, Ionta MT, Lai S, Perra MT, Atzori F, Minerba L, Pusceddu V, Maxia C, Murtas D, Demurtas P, Massidda B, Sirigu P: Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer.Eur J Histochem 2011, 55:e39.
18. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73. 10.1016/j.cell.2009.12.007, 20074520.
19. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, Gobbi A, Alcalay M, Minucci S, Pelicci PG. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009, 457:51-56. 10.1038/nature07618, 19122635.
20. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401. 10.1038/nature03128, 15549107.
21. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174. 10.1038/nm1483, 16998484.
22. Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, Lu P, Jin F. Co-expression of Oct-4 and Nestin in human breast cancers. Mol Biol Rep 2012, 39:5875-5881. 10.1007/s11033-011-1398-6, 22207173.
23. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013, 13:11-26. 10.1038/nrc3419, 23258168.
24. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB: Wnt pathway activity in breast cancer sub-types and stem-like cells.PLoS One 2013, 8:e67811.
25. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res 2012, 10:1597-1606. 10.1158/1541-7786.MCR-12-0155-T, 23071104.
26. Ahmad A, Sarkar SH, Bitar B, Ali S, Aboukameel A, Sethi S, Li Y, Bao B, Kong D, Banerjee S, Padhye SB, Sarkar FH. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol Cancer Ther 2012, 11:2193-2201. 10.1158/1535-7163.MCT-12-0232-T, 22821148.
27. Proffitt KD, Madan B, Ke Z, Pendharkar V, Ding L, Lee MA, Hannoush RN, Virshup DM. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res 2013, 73:502-507. 10.1158/0008-5472.CAN-12-2258, 23188502.
28. Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H, Xiang L, Gao P, Zhou G. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett 2012, 323:106-113. 10.1016/j.canlet.2012.03.039, 22484497.
29. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 2007, 104:618-623. 10.1073/pnas.0606599104, 17202265.
30. Oliveira LR, Jeffrey SS, Ribeiro-Silva A. Stem cells in human breast cancer. Histol Histopathol 2010, 25:371-385. 20054808.
31. Zhang J, Li Y, Liu Q, Lu W, Bu G. Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene 2010, 29:539-549. 10.1038/onc.2009.339, 19881541.
32. Liu BY, McDermott SP, Khwaja SS, Alexander CM. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci U S A 2004, 101:4158-4163. 10.1073/pnas.0400699101, 15020770.
33. Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, Chen B, Xu H, Jin F, Lu P. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg 2011, 253:1165-1171. 10.1097/SLA.0b013e318214c54e, 21394007.
34. Matsuda Y, Kure S, Ishiwata T. Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol 2012, 45:59-65. 10.1007/s00795-012-0571-x, 22718289.
35. Beck S, Jin X, Yin J, Kim SH, Lee NK, Oh SY, Jin X, Kim MK, Kim EB, Son JS, Kim SC, Nam DH, Kim SH, Kang SK, Kim H, Choi YJ. Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells. Biomaterials 2011, 32:8518-8528. 10.1016/j.biomaterials.2011.07.048, 21880363.
36. Kru¨ger K, Stefansson IM, Collett K, Arnes JB, Aas T, Akslen LA. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast 2013, 22:282-288. 10.1016/j.breast.2012.07.008, 22840462.
37. Macas J, Ku MC, Nern C, Xu Y, Bu¨hler H, Remke M, Synowitz M, Franz K, Seifert V, Plate KH, Kettenmann H, Glass R, Momma S. Generation of neuronal progenitor cells in response to tumors in the human brain. Stem Cells 2014, 32:244-257. 10.1002/stem.1581, 24170295.
38. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L: Brca1 breast tumors contain distinctCD44+/CD24- and CD133+cells with cancer stem cell characteristics.Breast Cancer Res 2008, 10:R10.
39. Wagner N, Wagner KD, Scholz H, Kirschner KM, Schedl A. Intermediate filament protein nestin is expressed in developing kidney and heart and might be regulated by the Wilms' tumor suppressor Wt1. Am J Physiol Regul Integr Comp Physiol 2006, 291:R779-R787. 16614054.
40. Yamahatsu K, Matsuda Y, Ishiwata T, Uchida E, Naito Z. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis. Int J Oncol 2012, 40:1345-1357. 22246533.
41. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26. 10.1016/j.devcel.2009.06.016, 19619488.
42. Choi CH, Lee BH, Ahn SG, Oh SH. Proteasome inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation of glycogen synthase kinase 3β. Biochem Biophys Res Commun 2012, 418:759-764. 10.1016/j.bbrc.2012.01.095, 22310719.
43. Zhu Y, Xu L, Zhang J, Xu W, Liu Y, Yin H, Lv T, An H, Liu L, He H, Zhang H, Liu J, Xu J, Lin Z. Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma. Cancer Sci 2013, 104:663-671. 10.1111/cas.12134, 23433103.